# Bharat Parenterals share price today (Bharat Parenterals Ltd, NSE: BPLPHARMA)

> Bharat Parenterals share price today: ₹1,893.10 at the NSE close on 3 November 2026, up 56.5% in a year. Bharat Parenterals (NSE: BPLPHARMA) is worth ₹1,305 crore, trades at a P/E of 1,051.9 and has closed between ₹903.55 and ₹2,111.50 over the past 52 weeks. > Bharat Parenterals Ltd's results are improving, and its P/E is near the top of its own history, higher than 100% of past readings. BPLPHARMA · Pharma - Formulators · data as of 3 November 2026. Page: https://www.sectoralpha.in/stocks/bharat-parenterals-ltd

Sector Alpha also publishes a daily newsletter that explains one Indian stock at a time: https://newsletter.sectoralpha.in/?utm_source=sectoralpha&utm_medium=ai_text&utm_campaign=llms

## Key numbers

- Price: ₹1,893.10 (+56.5% in a year)
- P/E: 1,051.9× (higher than 100% of the last 6.2 years)
- Revenue (Sep 2026): ₹136 Cr (+109.2% on a year ago)
- Profit (Sep 2026): ₹12.0 Cr
- Operating margin: 17.0% (+15.7 points on a year ago)
- ROCE: −2%, FY26

The main question: profits are rising, but only 33% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. ## What is the Bharat Parenterals share price today? Bharat Parenterals Ltd's share price was ₹1,893.10 at the close on 3 November 2026. It has been rising for 23 weeks. That is 31.4% above its average price over the last 200 trading days. In the last 52 weeks it traded between ₹904 and ₹2,112, and at that close it sat 82% of the way up from that low. Over the past 13 weeks it has done better than the NIFTY 500, and it has stayed ahead for 24 weeks in a row. Over the last 8.6 years the share price moved +976% while the NIFTY 500 moved +146%, so it is ahead of the index over that whole period. The chart above shows the 13-week comparison for every week. This page treats a rise as over when the price closes below its 200-day average on two Fridays in a row. ## What changed at Bharat Parenterals this quarter? Three changes stood out: revenue grew again in the September 2026 quarter, best operating margin in 16 quarters and highest quarterly profit in 16 quarters. 1. Revenue grew again in the September 2026 quarter Revenue was ₹136 crore, +109.2% on a year earlier (₹65 crore), after 4 quarters of decline. Why: Revenue rose because Innoxel's licensing business grew fast. Next results: check whether the main standalone business turns its September order book into sales and gross profit recovers. From the earnings call on 30 Oct 2026. 2. Best operating margin in 16 quarters Operating margin was 17% in the September 2026 quarter, against 1.3% a year earlier. Why: Margins rose because most of each extra rupee of revenue reached profit as Innoxel's business grew. From the earnings call on 30 Oct 2026. 3. Highest quarterly profit in 16 quarters Profit of ₹12 crore in the September 2026 quarter is the highest of the last 16 quarters. Why: Profit hit a record because most of each extra rupee of revenue reached profit as Innoxel's business grew. Next results: check whether profit holds, since licensing payments are uneven and the half year gives a better read. From the earnings call on 30 Oct 2026. ## What are Bharat Parenterals' latest quarterly results? For July to September 2026 (the quarter ended 30 September 2026), Bharat Parenterals reported revenue of ₹136 crore, up 109.2% from ₹65.0 crore a year earlier, and a profit of ₹12.0 crore, against a loss of ₹9.00 crore a year earlier. ### Bharat Parenterals results: July to September 2026 against a year earlier

| Measure | July to September 2026 | July to September 2025 | Change |
| --- | --- | --- | --- |
| Revenue | ₹136 crore | ₹65.0 crore | +109.2% |
| Profit | ₹12.0 crore | loss of ₹9.00 crore | n/a |
| Earnings per share | ₹13.67 | ₹−10.50 | n/a |
| Operating margin | 17.0% | 1.3% | +15.7 points |

The next results, for October to December 2026, are due by 14 February 2027: listed companies must publish quarterly results within 45 days of the quarter's end (60 days for the January to March quarter). Bharat Parenterals' management discussed these results on a call held on 30 October 2026; what it said is further down this page. (From the company's reported quarterly results (quarter ended 30 September 2026). Revenue and profit in ₹ crore.)

## What is the Bharat Parenterals share price history? Bharat Parenterals closed at ₹1,893.10 on 3 November 2026, up 56.5% from ₹1,209.50 a year earlier (31 October 2025) and up 385.5% over five years. Its highest weekly close since March 2018 was ₹2,111.50 on 28 September 2026. ### Bharat Parenterals share price: then and now

| When | Close | Change to 3 Nov 2026 |
| --- | --- | --- |
| 1 week ago · 23 Oct 2026 | ₹1,662.75 | +13.9% |
| 1 month ago · 1 Oct 2026 | ₹1,717.40 | +10.2% |
| 1 year ago · 31 Oct 2025 | ₹1,209.50 | +56.5% |
| 3 years ago · 3 Nov 2023 | ₹611.10 | +209.8% |
| 5 years ago · 4 Nov 2021 | ₹389.95 | +385.5% |
| Earliest weekly close in our records · 23 Mar 2018 | ₹175.90 | +976.2% |
| Highest weekly close since March 2018, also the 52-week high · 28 Sep 2026 | ₹2,111.50 | −10.3% |
| Lowest weekly close since March 2018 · 3 Aug 2018 | ₹133.30 | +1,320.2% |
| 52-week low (weekly close) · 1 Feb 2026 | ₹903.55 | +109.5% |

Weekly closing prices. Each change is the move from that price to the 3 Nov 2026 close. A day's intraday high or low can go beyond these weekly closes. (437 weekly closes from 23 March 2018 to 3 November 2026.)

## What is the latest news on Bharat Parenterals? 3 Nov 2026: Bharat Parenterals closed at ₹1,893.10, up 13.9% on the week and up 10.2% on the month. 30 Oct 2026: Bharat Parenterals held its results call for July to September 2026. Management guided: Standalone revenue growth 10-15% on FY26 ₹234 crore base with operating margin 10-15%. ### Earlier

- Results for July to September 2026: Revenue up 109.2% on a year earlier. - 11 Sep 2026: ex-date for a dividend of ₹1 a share, record date 12 Sep 2026. ## What dividend does Bharat Parenterals pay? Bharat Parenterals paid ₹1 a share in regular dividends in the 12 months to 4 November 2026 (1 payment), a yield of 0.05% at the ₹1,893.10 close on 3 November 2026. The last was a dividend of ₹1 a share, ex-date 11 September 2026. ### Bharat Parenterals dividends since 1 April 2021

| Ex-date | Dividend per share | Type | Record date |
| --- | --- | --- | --- |
| 11 Sep 2026 | ₹1 | Dividend | 12 Sep 2026 |

Amounts as the company declared them on the NSE. A dividend goes to whoever owns the shares before the ex-date. 0 of 5 Of the last 5 financial years, years with an NSE dividend record

Not in its latest year. Bharat Parenterals Ltd paid out 0% of its profit as dividends in FY26. It did pay a dividend in 2 of its last 11 reported years, so there is a history but no current dividend. (From the NSE corporate-actions record, read 4 November 2026.)

## What did Bharat Parenterals management say on the latest results call? On the call for July to September 2026, held on 30 October 2026, Bharat Parenterals' management guided: Standalone revenue growth 10-15% on FY26 ₹234 crore base with operating margin 10-15%. > “Innoxel's cost base is largely fixed. Between Q1 and Q2, revenue went up by 23.1 crores, and EBITDA went up by 16.5 crores. Put simply, most of each additional rupee of revenue is now flowing through to profit.”
> Bahim Desai, on the call for July to September 2026

### What management guided

- Innoxel revenue growth 35-45% at operating margin 20-25% including out-licensing roughly ₹80-90 crores with second-half timing to decide revisit in Q3. - Varenyam Healthcare revenue growth 20-25% at operating margin 8-13% with taper to Q4 and new division cost in band. - Second CMO product commercialisation within FY27 upon USFDA approval with supply ramp through second half. - First own CDMO product in October to December 2027 as 505(b)(2) plus liposomal exhibit November with filing Q1 next year. Management’s own plans and goals, from our notes of the call. A plan is not a result. Source: [the call transcript](https://files.tijoristack.ai/concall/transcript/7026-30-Oct-2026.pdf). (From the call for July to September 2026, 30 October 2026.)

## What to watch in Bharat Parenterals' next results? When Bharat Parenterals reports October to December 2026, these are the 3 checks that show whether the story is still on course. First: Standalone H2 conversion of September book and gross recovery as pre-rise pricing turns over or input costs ease. - What to check (from the call)
- Standalone H2 conversion of September book and gross recovery as pre-rise pricing turns over or input costs ease. - Innoxel second-product USFDA decision and binding forecast pace on first oral-liquid supply with manufacturing revenue starting. - H2 licensing and milestone timing versus full-year range with revisit flagged for Q3 as supply ramp builds. ## Which stock lists is Bharat Parenterals on? Bharat Parenterals is on 2 of our India lists: Momentum stocks and Pharma stocks. - [Momentum stocks Market cap cr: 1326.014089364008](https://www.sectoralpha.in/momentum-stocks-india)
- [Pharma stocks Market value (₹ crore): 1326.014089364008](https://www.sectoralpha.in/sectors/pharma-stocks-india)

## Is Bharat Parenterals profitable? Bharat Parenterals Ltd earned ₹12.0 Cr of net profit in the Sep 2026 quarter. The full FY26 year was a loss of ₹27.0 Cr. That is 8.8% of the quarter's revenue. The same quarter a year earlier lost ₹9.0 Cr. 10 of the last 12 reported quarters were loss-making. ## How much revenue does Bharat Parenterals make, and is it growing? Bharat Parenterals Ltd reported ₹136 Cr of revenue in the Sep 2026 quarter, +109.2% on the same quarter a year earlier. Over 10 years it has grown 10.8% a year on average. The last full year, FY26, came in at ₹345 Cr. The last four reported quarters add to ₹395 Cr. FY26 revenue was ₹345 Cr, +1.5% on the year before. Recent pace: the last four quarters grew +19.2% on average, against 10.8% a year over the longer run, so this year is growing faster than its own long-run rate. Is growth speeding up? Revenue over the last 12 months grew +10.6%, against +16.1% a year over the last 8 quarters (rolling over). ## How much of every ₹100 of sales does Bharat Parenterals keep? Bharat Parenterals Ltd's operating margin was 17.0% in the Sep 2026 quarter, 15.7 percentage points higher than the same quarter a year ago. Across 11 years it has been between 1.1% and 14.0%. The latest quarter is above every full year in that period. Why the margin moved: operating margin changed +16.0 percentage points on the year while gross margin changed −8.7 points. So the gain came mostly from costs below the gross margin, such as staff and overheads, measured against sales. ## Is Bharat Parenterals' profit turning into cash? Over the last 3 years, 33% of Bharat Parenterals Ltd's reported profit came in as cash from its operations, a gap worth watching. In FY26 it brought in ₹38.0 Cr of operating cash against −₹27.0 Cr of profit. After ₹41.0 Cr of spending on assets, free cash was −₹3.0 Cr: it spent more than its operations brought in. Cash-flow figures here are yearly, because quarterly cash statements are not published, so this section changes once a year. Why 33% of profit came in as cash: the cash cycle got 88 days longer between FY21 and FY26, so more of each rupee of profit waits in the business before it arrives. When less than 70% of profit comes in as cash, it is the thing to watch on this page. What to look at next: less of the profit turns into cash than it should, and the cash cycle is 88 days longer. The next section looks at where the cash is stuck. ## Where does Bharat Parenterals' cash go? Bharat Parenterals Ltd's cash cycle, the days between paying suppliers and getting paid by customers, was 199 days in FY26, up from 111 days in FY21. It spent ₹227 Cr on assets over the last 3 years. Customers take 159 days to pay, and stock sits for 162 days on average. At FY26 sales of ₹345 Cr, each day of that cycle ties up about ₹0.9 Cr, so roughly ₹188 Cr is tied up in the business at any time. FY26: customers took 159 days to pay and stock sat for 162 days, about 5.3 months of sales sitting as stock, for a full cycle of 199 days, longer than FY21's 111. The full loop: cash goes out to suppliers and production on day 0. Stock sits for 162 days. Customers pay about 159 days after that. Suppliers are paid at 122 days. Together that makes the 199-day cycle. Spending on assets: ₹227 Cr over the last 3 years, against ₹78.0 Cr of depreciation (the yearly wear and tear on existing assets). So it is building well beyond replacing what wears out. Work still in progress is ₹35.0 Cr (FY26): assets paid for that are not earning yet. In short: cash is getting stuck in the daily cycle, so watch the cycle more than the profit. ## What is Bharat Parenterals' P/E ratio, and how does it compare with its own history? Bharat Parenterals Ltd's P/E is 1,051.9×, about the highest it has ever been. Its usual P/E (the middle reading) is 11.1×, over 6.2 years of weekly prices. This compares the share price with the company’s own past. It does not say what the business is worth. Where the price move came from: over 5 years the price moved +37.2% a year; about +13.4% a year came from earnings growth and about +23.8 percentage points from the multiple (the market paying more). The split is approximate (price return minus earnings growth). It shows how much of the move came from the market paying a different multiple. In short: the multiple is high against its own past, so the earnings trend underneath matters more than the multiple. A quarterly PEG curve, which only the second data source has, is not shown on this page: its two data sources disagree by up to 989% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Is the Bharat Parenterals business getting better or worse? Bharat Parenterals Ltd's business trend cannot be read yet. There are fewer than eight usable quarters of growth figures, so there is not enough history to read the trend. This is based on 9 quarters of 2 measures, with some gaps. Why it matters: with too little history, we say so rather than guess a direction. One or more growth lines have an extreme jump caused by comparing with a near-zero or loss-making quarter. Those jumps are capped before reading and drawn at the edge of the chart, so one odd quarter does not decide the result. The return figures here are yearly, not quarterly. They show level and direction only; they can support the growth lines but never decide the reading alone. There are fewer than eight usable quarters, so this page does not guess a direction from so little history. ## How much does Bharat Parenterals earn on its capital? Bharat Parenterals Ltd earned a ROCE of −2% in FY26. That is up from a low of −4% in FY25. We cannot compare its return on capital used with its cost of capital from the data we have. It comes from a −7.8% net margin and 0.56× asset turnover (sales divided by assets). Why the return is what it is (FY26): a −7.8% net margin × 0.56× asset turnover × 1.90× leverage (assets divided by equity) ≈ −8.3% on equity. The margin does its share; borrowing is a big part of it. The quarterly return lines and the return-on-capital-used (ROIC) line, which only the second data source has, are not shown on this page: its two data sources disagree by up to 989% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## Does Bharat Parenterals have too much debt? Bharat Parenterals Ltd had ₹146 Cr of borrowings against ₹322 Cr of equity in FY26, so its debt is 0.45× its equity. Its operating profit is 1 times its interest bill. Over 5 years borrowings went from ₹12.0 Cr to ₹146 Cr. Over the last 3 of those years it spent ₹227 Cr on assets. Part of the spending on assets is being paid for with borrowed money. The total-debt and debt-to-equity series, which only the second data source has, are not shown on this page: its two data sources disagree by up to 989% on reported income across 15 comparable periods. When two sources disagree on a figure, we leave it out on purpose. The gap is a choice, not missing data. ## What is the Bharat Parenterals shareholding pattern? Promoters raised their stake in Bharat Parenterals Ltd by 1.9 percentage points over 8 quarters, the biggest change among its owners. Promoters now own 67.2% of the company. Domestic institutions moved +0.7 points over the same period, to 1.3%. This uses the four owner groups that companies report every quarter; nothing is guessed between filings. Over the last two years: Promoters: +1.9 points over 8 quarters, to 67.2%; Domestic institutions: +0.7 points over 8 quarters, to 1.3%; Foreign institutions: +0.0 points over 8 quarters, to 0.1%. Why the owners changed: promoters drove it (+1.9 points), together with domestic institutions (+0.7 points). They raised their stake step by step. ## How far is Bharat Parenterals from balance-sheet trouble? For Bharat Parenterals Ltd, the Z-score is not available, so we say so rather than guess one. It estimates how far the balance sheet is from trouble; it is not a forecast of failure. The debt, cash-flow and return sections show the balance-sheet figures we do have, each with its own date. ## How does Bharat Parenterals rank in its industry? 45.9 out of 100, rank 27 of 44 in Pharma - Formulators, with 52% of the evidence available. Bharat Parenterals Ltd scores 45.9 out of 100 against the 44 companies it is compared with in Pharma - Formulators, ranking 27. Some evidence is missing, so the score is pulled toward the middle on purpose. The four parts add up to the total exactly: 19.9 + 5.3 + 8.5 + 12.2 = 45.9. This is the same number shown on the industry page; it is worked out once for the whole group and read here. What would change it: The score would fall if profit growth turns negative or margins stop improving while the share price lags its sector. ## Which companies is Bharat Parenterals compared with? Bharat Parenterals ranks 27 of 44 Pharma - Formulators companies on the 4-Factor Sector Score, with 45.9 out of 100. 1. [Rubicon Research Ltd](https://www.sectoralpha.in/stocks/rubicon-research-ltd) RUBICON · leader · Most evidence points up · 83% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.1/35 · Revenue 46.8% · Profit 91.4% · Operating margin change 2 points · 88% evidence Capital efficiency 18.6/25 · ROCE 28.4% · Operating margin 24% · 100% evidence Valuation 6.2/20 · P/E 92.5× · PEG 2.31 · 65% evidence Relative strength 16.5/20 · Lead over its industry 28.1% · Lead over NIFTY 500 53.6% · 1 year 160.5% · 70% evidence · 11 of 12 weeks ahead Exact sum: 30.1 + 18.6 + 6.2 + 16.5 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 2. [Kwality Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/kwality-pharmaceuticals-ltd) KPL · breaking out · Most evidence points up · 81% evidence 71.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.9/35 · Revenue 37.9% · Profit 88.4% · Operating margin change 3 points · 88% evidence Capital efficiency 18.2/25 · ROCE 24.1% · Operating margin 25% · 100% evidence Valuation 11.0/20 · P/E 44.2× · PEG 0.54 · 100% evidence Relative strength 12.3/20 · Lead over its industry n/a · Lead over NIFTY 500 74.4% · 1 year 288.9% · 25% evidence · 9 of 9 weeks ahead Exact sum: 29.9 + 18.2 + 11 + 12.3 = 71.4 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 3. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ACCENTMIC · leader · Most evidence points up · 65% evidence 70.5 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 21.4/35 · Revenue n/a · Profit n/a · Operating margin change 7 points · 27% evidence Capital efficiency 21.4/25 · ROCE 24.9% · Operating margin 24% · 100% evidence Valuation 9.1/20 · P/E 26.9× · PEG n/a · 50% evidence Relative strength 18.6/20 · Lead over its industry 21.4% · Lead over NIFTY 500 47.6% · 1 year 132.1% · 100% evidence · 12 of 12 weeks ahead Exact sum: 21.4 + 21.4 + 9.1 + 18.6 = 70.5 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 4. [Ajanta Pharma Ltd](https://www.sectoralpha.in/stocks/ajanta-pharma-ltd) AJANTPHARM · leader · Most evidence points up · 100% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 30.3/35 · Revenue 25% · Profit 29.8% · Operating margin change 7 points · 100% evidence Capital efficiency 21.3/25 · ROCE 34.5% · Operating margin 31% · 100% evidence Valuation 7.1/20 · P/E 34.7× · PEG 1.77 · 100% evidence Relative strength 10.5/20 · Lead over its industry -3.5% · Lead over NIFTY 500 20% · 1 year 42.3% · 100% evidence · 11 of 12 weeks ahead Exact sum: 30.3 + 21.3 + 7.1 + 10.5 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 5. [Glenmark Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/glenmark-pharmaceuticals-ltd) GLENMARK · breaking out · Most evidence points up · 86% evidence 69.2 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.1/35 · Revenue 32.9% · Profit 100% · Operating margin change 2 points · 88% evidence Capital efficiency 20.3/25 · ROCE 39.8% · Operating margin 20% · 100% evidence Valuation 11.2/20 · P/E 20.8× · PEG n/a · 50% evidence Relative strength 8.6/20 · Lead over its industry -11.4% · Lead over NIFTY 500 10.8% · 1 year 21.5% · 100% evidence · 9 of 12 weeks ahead Exact sum: 29.1 + 20.3 + 11.2 + 8.6 = 69.2 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 6. [Bliss GVS Pharma Ltd](https://www.sectoralpha.in/stocks/bliss-gvs-pharma-ltd) BLISSGVS · leader · Most evidence points up · 82% evidence 67.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 29.3/35 · Revenue 25% · Profit 43.1% · Operating margin change 8 points · 95% evidence Capital efficiency 14.7/25 · ROCE 16.9% · Operating margin 26% · 76% evidence Valuation 6.4/20 · P/E 42.4× · PEG n/a · 50% evidence Relative strength 16.7/20 · Lead over its industry 59% · Lead over NIFTY 500 86.2% · 1 year 312.8% · 100% evidence · 12 of 12 weeks ahead Exact sum: 29.3 + 14.7 + 6.4 + 16.7 = 67.1 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 7. [Fredun Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/fredun-pharmaceuticals-ltd) FREDUN · breaking out · Most evidence points up · 76% evidence 65.8 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 31.9/43.75 · Revenue 50.3% · Profit 91.3% · Operating margin change 0 points · 88% evidence Capital efficiency 19.0/31.25 · ROCE 21.5% · Operating margin 14% · 100% evidence Valuation 14.9/25 · P/E 52.7× · PEG 0.77 · 100% evidence Relative strength: no reading this week · its 20 points are shared across the other three Exact sum: 31.9 + 19 + 14.9 = 65.8 (no relative-strength reading this week; its 20 points are shared across the other three) · What this means: There is no relative-strength reading for this week, so the score is built from earnings, capital efficiency and valuation alone. 8. [Lupin Ltd](https://www.sectoralpha.in/stocks/lupin-ltd) LUPIN · quiet · Most evidence points up · 89% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 27.9/35 · Revenue 28.2% · Profit 49.2% · Operating margin change 2 points · 88% evidence Capital efficiency 19.4/25 · ROCE 29.9% · Operating margin 30% · 100% evidence Valuation 16.1/20 · P/E 15.4× · PEG 0.54 · 65% evidence Relative strength 2.0/20 · Lead over its industry -24.5% · Lead over NIFTY 500 -4.7% · 1 year 2.4% · 100% evidence · 0 of 12 weeks ahead Exact sum: 27.9 + 19.4 + 16.1 + 2 = 65.4 · What this means: Earnings are strong; relative strength in its sector is -24.5% and the one-year return is 2.4%. 9. [Ipca Laboratories Ltd](https://www.sectoralpha.in/stocks/ipca-laboratories-ltd) IPCALAB · turning · Most evidence points up · 78% evidence 65.4 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 24.0/35 · Revenue 10.6% · Profit 68% · Operating margin change 6 points · 83% evidence Capital efficiency 15.7/25 · ROCE 17% · Operating margin 24% · 76% evidence Valuation 11.0/20 · P/E 35.6× · PEG n/a · 50% evidence Relative strength 14.7/20 · Lead over its industry -0.5% · Lead over NIFTY 500 23.6% · 1 year 51.7% · 100% evidence · 10 of 12 weeks ahead Exact sum: 24 + 15.7 + 11 + 14.7 = 65.4 · What this means: The evidence is balanced: no factor stands out, so another reported quarter is needed before the picture is clearer. 10. [Marksans Pharma Ltd](https://www.sectoralpha.in/stocks/marksans-pharma-ltd) MARKSANS · leader · Evidence leans up · 74% evidence 64.1 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 28.7/35 · Revenue 19.6% · Profit 48% · Operating margin change 9 points · 88% evidence Capital efficiency 17.2/25 · ROCE 18.8% · Operating margin 25% · 100% evidence Valuation 6.3/20 · P/E 26.8× · PEG 2.85 · 65% evidence Relative strength 11.9/20 · Lead over its industry n/a · Lead over NIFTY 500 40.1% · 1 year 68.4% · 25% evidence · 12 of 12 weeks ahead Exact sum: 28.7 + 17.2 + 6.3 + 11.9 = 64.1 · What this means: Earnings, capital efficiency and relative strength all agree. The open questions are about management, upcoming events and risks. 11. [FDC Ltd](https://www.sectoralpha.in/stocks/fdc-ltd) FDC · basing · Evidence leans up · 85% evidence 62.8 out of 100 Growth Capital Valuation Relative
12. [Corona Remedies Ltd](https://www.sectoralpha.in/stocks/corona-remedies-ltd) CORONA · turning · Evidence leans up · 73% evidence 62.5 out of 100 Growth Capital Valuation Relative
13. [Emcure Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/emcure-pharmaceuticals-ltd) EMCURE · losing its lead · Evidence leans up · 71% evidence 61.8 out of 100 Growth Capital Valuation Relative
14. [Mankind Pharma Ltd](https://www.sectoralpha.in/stocks/mankind-pharma-ltd) MANKIND · turning · Evidence leans up · 100% evidence 61.0 out of 100 Growth Capital Valuation Relative
15. [Zydus Lifesciences Ltd](https://www.sectoralpha.in/stocks/zydus-lifesciences-ltd) ZYDUSLIFE · leader · Evidence leans up · 96% evidence 58.1 out of 100 Growth Capital Valuation Relative
16. [Gufic BioSciences Ltd](https://www.sectoralpha.in/stocks/gufic-biosciences-ltd) GUFICBIO · leader · Evidence leans up · 71% evidence 56.2 out of 100 Growth Capital Valuation Relative
17. [ERIS Lifesciences Ltd](https://www.sectoralpha.in/stocks/eris-lifesciences-ltd) ERIS · basing · Evidence leans up · 67% evidence 56.1 out of 100 Growth Capital Valuation Relative
18. [Strides Pharma Science Ltd](https://www.sectoralpha.in/stocks/strides-pharma-science-ltd) STAR · breaking out · Evidence leans up · 75% evidence 55.3 out of 100 Growth Capital Valuation Relative
19. [Caplin Point Laboratories Ltd](https://www.sectoralpha.in/stocks/caplin-point-laboratories-ltd) CAPLIPOINT · losing its lead · Evidence leans up · 96% evidence 54.3 out of 100 Growth Capital Valuation Relative
20. [Wockhardt Ltd](https://www.sectoralpha.in/stocks/wockhardt-ltd) WOCKPHARMA · losing its lead · Evidence leans up · 71% evidence 52.8 out of 100 Growth Capital Valuation Relative
21. [Kilitch Drugs (India) Ltd](https://www.sectoralpha.in/stocks/kilitch-drugs-indialtd) KILITCH · breaking out · Evidence leans up · 78% evidence 51.3 out of 100 Growth Capital Valuation Relative
22. [Akums Drugs & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/akums-drugs-pharmaceuticals-ltd) AKUMS · leader · Evidence leans up · 71% evidence 50.9 out of 100 Growth Capital Valuation Relative
23. [Alkem Laboratories Ltd](https://www.sectoralpha.in/stocks/alkem-laboratories-ltd) ALKEM · quiet · Evidence leans down · 78% evidence 47.6 out of 100 Growth Capital Valuation Relative
24. [Alembic Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/alembic-pharmaceuticals-ltd) APLLTD · turning · Evidence leans down · 81% evidence 46.9 out of 100 Growth Capital Valuation Relative
25. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) BAJAJHCARE · quiet · Evidence leans down · 100% evidence 46.5 out of 100 Growth Capital Valuation Relative
26. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) LINCOLN · quiet · Evidence leans down · 100% evidence 46.0 out of 100 Growth Capital Valuation Relative
27. Bharat Parenterals Ltd this page BPLPHARMA · breaking out · Too little evidence to rank firmly · 52% evidence 45.9 out of 100 Growth Capital Valuation Relative How the score adds up Growth & earnings 19.9/35 · Revenue 10.6% · Profit 63% · Operating margin change 15.7 points · 71% evidence Capital efficiency 5.3/25 · ROCE -1.9% · Operating margin 17% · 76% evidence Valuation 8.5/20 · P/E 1128× · PEG n/a · 15% evidence Relative strength 12.2/20 · Lead over its industry n/a · Lead over NIFTY 500 62.2% · 1 year 67.6% · 25% evidence · 5 of 5 weeks ahead Exact sum: 19.9 + 5.3 + 8.5 + 12.2 = 45.9 · What this means: Some evidence is missing, so the score is pulled toward the middle on purpose. 28. [Aurobindo Pharma Ltd](https://www.sectoralpha.in/stocks/aurobindo-pharma-ltd) AUROPHARMA · leader · Evidence leans down · 96% evidence 45.7 out of 100 Growth Capital Valuation Relative
29. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) AMRUTANJAN · turning · Evidence leans down · 96% evidence 44.9 out of 100 Growth Capital Valuation Relative
30. [RPG Life Sciences Ltd](https://www.sectoralpha.in/stocks/rpg-life-sciences-ltd) RPGLIFE · losing its lead · Evidence leans down · 100% evidence 43.1 out of 100 Growth Capital Valuation Relative
31. [J B Chemicals & Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/j-b-chemicals-pharmaceuticals-ltd) JBCHEPHARM · Too little evidence to rank firmly · 59% evidence 42.6 out of 100 Growth Capital Valuation Relative
32. [Zim Laboratories Ltd](https://www.sectoralpha.in/stocks/zim-laboratories-ltd) ZIMLAB · leader · Evidence leans down · 71% evidence 42.2 out of 100 Growth Capital Valuation Relative
33. [Sun Pharmaceutical Industries Ltd](https://www.sectoralpha.in/stocks/sun-pharmaceutical-industries-ltd) SUNPHARMA · quiet · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
34. [Dr Reddys Laboratories Ltd](https://www.sectoralpha.in/stocks/dr-reddys-laboratories-ltd) DRREDDY · turning · Evidence leans down · 100% evidence 39.4 out of 100 Growth Capital Valuation Relative
35. [Natco Pharma Ltd](https://www.sectoralpha.in/stocks/natco-pharma-ltd) NATCOPHARM · quiet · Evidence leans down · 96% evidence 38.8 out of 100 Growth Capital Valuation Relative
36. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) BAFNAPH · breaking out · Evidence leans down · 74% evidence 35.8 out of 100 Growth Capital Valuation Relative
37. [Cipla Ltd](https://www.sectoralpha.in/stocks/cipla-ltd) CIPLA · turning · Evidence leans down · 100% evidence 35.4 out of 100 Growth Capital Valuation Relative
38. [Torrent Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/torrent-pharmaceuticals-ltd) TORNTPHARM · losing its lead · Most evidence points down · 100% evidence 34.6 out of 100 Growth Capital Valuation Relative
39. [Biocon Ltd](https://www.sectoralpha.in/stocks/biocon-ltd) BIOCON · quiet · Most evidence points down · 96% evidence 34.4 out of 100 Growth Capital Valuation Relative
40. [Suven Life Sciences Ltd](https://www.sectoralpha.in/stocks/suven-life-sciences-ltd) SUVEN · quiet · Most evidence points down · 64% evidence 33.1 out of 100 Growth Capital Valuation Relative
41. [Influx Healthtech Ltd](https://www.sectoralpha.in/stocks/influx-healthtech-ltd) INFLUX · quiet · Too little evidence to rank firmly · 42% evidence 49.7 out of 100 Growth Capital Valuation Relative
42. [Syncom Healthcare Ltd](https://www.sectoralpha.in/stocks/syncom-healthcare-ltd) SYNCOM · Too little evidence to rank firmly · 17% evidence 42.3 out of 100 Growth Capital Valuation Relative
43. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) INDOCO · losing its lead · Too little evidence to rank firmly · 49% evidence 38.4 out of 100 Growth Capital Valuation Relative
44. [Sai Parenterals Ltd](https://www.sectoralpha.in/stocks/sai-parenterals-ltd) SAIPARENT · turning · Too little evidence to rank firmly · 31% evidence 36.7 out of 100 Growth Capital Valuation Relative

Missing figures are not scored as bad. They lower the confidence and pull the final score toward the middle. Relative strength counts only when the company has a reading for this week; with no reading, that factor is left out and its 20 points are shared across the other three in proportion. PEG is not shown when the ratio cannot mean anything: the company must be making a profit, its price-to-earnings must be positive, and its three-year earnings growth must fall between 5% and 60%. Dividing a price multiple by a loss, or by growth measured off a tiny base, produces a number that looks precise and tells you nothing. Under relative strength, one mark per week shows the last 12 weeks: a mark is filled where the company led NIFTY 500 by 5% or more over the 13 weeks ending that week, which is the same test used everywhere on this site. Price stage places the company on the same six-step path the industry is placed on (basing, turning, breaking out, leader, fading, asleep), read from how many weeks running it has led NIFTY 500 and whether that lead is growing or shrinking. It describes where the share price stands, not the direction of earnings, and it is not a recommendation; it is left blank for a company whose weekly history is too short or too stale to read. The figures in this ranking come from the industry comparison: results through the Sep 2026 quarter, and the P/E at that quarter's end. The sections above use the latest weekly price, so a P/E or return there can differ a little from the one here. The stage words in this ranking (such as losing its lead or breaking out) describe the lead over the index, not the price phase in the price section. Related companies: [Pharma - Formulators](https://www.sectoralpha.in/sectors/pharma-formulators), all 44 compared on one page. ## Which companies are close to Bharat Parenterals in size? Bharat Parenterals is the 37th largest of 44 Pharma - Formulators companies on Sector Alpha by market value (scores of 30 October 2026). Just above it: Indoco Remedies, Accent Microcell and Amrutanjan Health Care. Just below it: Bafna Pharmaceuticals, Bajaj Healthcare and Lincoln Pharmaceuticals. ### Pharma - Formulators companies close in size

1. [Indoco Remedies Ltd](https://www.sectoralpha.in/stocks/indoco-remedies-ltd) ₹1,923 crore
2. [Accent Microcell Ltd](https://www.sectoralpha.in/stocks/accent-microcell-ltd) ₹1,533 crore
3. [Amrutanjan Health Care Ltd](https://www.sectoralpha.in/stocks/amrutanjan-health-care-ltd) ₹1,436 crore
4. Bharat Parenterals Ltd ₹1,399 crore
5. [Bafna Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/bafna-pharmaceuticals-ltd) ₹1,060 crore
6. [Bajaj Healthcare Ltd](https://www.sectoralpha.in/stocks/bajaj-healthcare-ltd) ₹1,031 crore
7. [Lincoln Pharmaceuticals Ltd](https://www.sectoralpha.in/stocks/lincoln-pharmaceuticals-ltd) ₹1,000 crore

[All 44 Pharma - Formulators companies, largest first](https://www.sectoralpha.in/sectors/pharma-formulators#all-companies)

### Companies close in size in other industries

1. [Servotech Renewable Power System Ltd](https://www.sectoralpha.in/stocks/servotech-renewable-power-system-ltd) ₹1,402 crore · Capital Goods - Electric General
2. [Mahanagar Telephone Nigam Ltd](https://www.sectoralpha.in/stocks/mahanagar-telephone-nigam-ltd) ₹1,400 crore · Telecom Services
3. Bharat Parenterals Ltd ₹1,399 crore
4. [Sobhagya Mercantile Ltd](https://www.sectoralpha.in/stocks/sobhagya-mercantile-ltd) ₹1,397 crore · Diversified
5. [MIRC Electronics Ltd](https://www.sectoralpha.in/stocks/mirc-electronics-ltd) ₹1,394 crore · Consumer Electronics

## What else do people ask about Bharat Parenterals? ### What is Bharat Parenterals's share price today? Bharat Parenterals Ltd's share price is ₹1,893.10, +56.5% over the past year. The whole company is worth ₹1,305 Cr on the market. In the last 52 weeks it traded between ₹904 to ₹2,112; today it is 82% of the way up from the low, 31.4% above its 200-day average (as of 3 November 2026). ### What were Bharat Parenterals's latest quarterly results? Bharat Parenterals Ltd reported revenue of ₹136 Cr and net profit of ₹12.0 Cr for the Sep 2026 quarter. Earnings per share were ₹13.67. The operating margin was 17.0%, 15.7 percentage points higher than a year earlier (as of 3 November 2026). ### What is Bharat Parenterals's market cap? Bharat Parenterals Ltd's market capitalisation is ₹1,305 Cr at a share price of ₹1,893.10. Market cap is the share price times the number of shares, so it changes whenever the price moves (as of 3 November 2026). ### How is Bharat Parenterals performing? Bharat Parenterals Ltd's share price has been rising for 23 weeks. Over the past 13 weeks it has done better than the NIFTY 500, for 24 weeks running. This describes what the data did, not a rating (as of 3 November 2026). ### Will Bharat Parenterals's share price go up? This page does not forecast Bharat Parenterals Ltd's share price. What it shows instead: the share price is ₹1,893.10, and it has been rising for 23 weeks. Its P/E of 1,051.9× is higher than 100% of its own last 6 years (as of 3 November 2026). ### Where is Bharat Parenterals in its business cycle? Bharat Parenterals Ltd's FY26 operating margin was 4.6%, against a 11-year range of 1.1% to 14.0%: the middle of its own range, neither a peak nor a low. The latest quarter was 17.0%. Comparing margins with a company's own long history is a good way to see where it is in its cycle (as of 3 November 2026). ### What could break the Bharat Parenterals story? The main question: profits are rising, but only 33% of the last 3 years' profit came in as cash from operations. The gap between reported profit and actual cash is the thing to watch. On price, this page treats a rise as over when the share price closes below its 200-day average on two Fridays in a row (as of 3 November 2026). ### Is Bharat Parenterals a stock worth studying right now? What the numbers show: Bharat Parenterals Ltd's results are improving, and its P/E is near the top of its own history, higher than 100% of past readings. The main open question: whether the cash starts to follow the profit. Every number on this page is worked out by code from the published figures, with no forecasts and no price opinions (as of 3 November 2026). ### Is there a Bharat Parenterals share price forecast for 2026? What management itself guided: Standalone revenue growth 10-15% on FY26 ₹234 crore base with operating margin 10-15%. ## Lists

- Momentum stocks: https://www.sectoralpha.in/momentum-stocks-india
- Pharma stocks: https://www.sectoralpha.in/sectors/pharma-stocks-india

This is research, not advice. We’re not SEBI-registered.